文献速递呼吸危重症与机械通气呼吸道感染

血清过氧化物还原酶1升高是ARDS多器官衰竭的生物标志物

Elevated serum peroxiredoxin 1 is a biomarker of multiorgan failure in ARDS
RSS 订阅 · BMJ Open Respiratory Research

这项回顾性队列研究纳入90例ARDS患者,发现血清PRDX1水平显著升高,尤其在多器官损伤患者中;多因素分析显示PRDX1和年龄是28天死亡的独立危险因素,ROC曲线AUC=0.776(p<0.0001),与APACHE II评分(AUC=0.778,p<0.0001)相当,并在20例验证队列及LPS诱导的急性肺损伤和脓毒症相关急性肺损伤小鼠模型中得到验证。

要点

  • 血清PRDX1在90例ARDS患者中显著升高,多器官损伤者尤为明显。
  • PRDX1和年龄是ARDS患者28天死亡的独立危险因素。
  • PRDX1预测28天死亡的AUC=0.776(p<0.0001),与APACHE II评分(AUC=0.778,p<0.0001)相当。

核心结论

  • 血清PRDX1在ARDS患者中显著升高,尤其在多器官损伤患者中,并显示作为预后生物标志物的潜力,与28天死亡率相关。

研究设计与样本

  • 回顾性队列研究,在湘雅三医院纳入90例ARDS患者,另从湘雅医院重症监护病房招募20例ARDS患者作为独立验证队列。
  • 采用多因素logistic回归和受试者工作特征(ROC)曲线分析评估循环PRDX1对28天死亡的预后价值。
  • 在LPS诱导的急性肺损伤(ALI)和脓毒症相关ALI小鼠模型中评估血清Prdx1动态变化。

主要发现

  • 90例ARDS患者血清PRDX1水平显著升高,尤其在多器官损伤患者中。
  • 多因素分析确定PRDX1和年龄为28天死亡的独立危险因素。
  • ROC曲线显示PRDX1的预后价值(AUC=0.776,p<0.0001),与APACHE II评分(AUC=0.778,p<0.0001)相当。
  • 上述发现在20例患者验证队列中得到验证。
  • 动物实验证实血清PRDX1与肺损伤严重程度正相关,并在多器官损伤情况下表现出更早升高和更高丰度。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background Acute respiratory distress syndrome (ARDS) is a heterogeneous clinical syndrome with high morbidity and mortality. Despite advances in understanding its pathophysiology, definitive biomarkers for ARDS disease stratification and management remain lacking. This study evaluated the utility of circulating PRDX1 in predicting 28-day mortality in ARDS patients. Methods A retrospective cohort study was conducted at Third Xiangya Hospital, enrolling 90 ARDS patients. Serum PRDX1 levels and clinical data were collected and compared with those from healthy volunteers and non-ARDS pneumonia patients to examine its alterations in ARDS patients; multivariate logistic regression and receiver operating characteristic (ROC) curve analyses were then employed to assess the prognostic value of circulating PRDX1 for 28-day mortality. An independent validation cohort of 20 ARDS patients was recruited from Xiangya Hospital intensive care units. Additionally, serum Prdx1 dynamics were assessed in LPS-induced acute lung injury (ALI) and sepsis-associated ALI murine models. Results Serum PRDX1 levels were significantly elevated in a cohort of 90 ARDS patients, particularly among those with multiorgan injury. Multivariate analysis identified PRDX1 and age as independent risk factors for 28-day mortality. ROC curves revealed PRDX1’s prognostic utility (area under the curve, AUC=0.776, p<0.0001), which was comparable to the APACHE II score (AUC=0.778, p<0.0001). These findings were validated in the 20-patient cohort. Animal experiments confirmed that serum PRDX1 positively correlated with lung injury severity and exhibited earlier elevation and higher abundance in multiorgan injury contexts. Conclusions Serum PRDX1 was significantly elevated in ARDS patients, particularly in those with multiorgan injury, and demonstrated potential as a prognostic biomarker, showing correlation with 28-day mortality. Its integration into the ARDS management framework holds significant potential for improving clinical outcomes.

来源:BMJ Open Respiratory Research,查看原文。版权归原作者所有。

引用

  1. BMJ Open Respiratory Research:Elevated serum peroxiredoxin 1 is a biomarker of multiorgan failure in ARDS

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。